{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ezetimibe+placebo&page=3",
    "query": {
      "intervention": "Ezetimibe placebo",
      "page": 3
    },
    "page_size": 10
  },
  "pagination": {
    "page": 3,
    "page_size": 10,
    "total_count": 53,
    "total_pages": 6,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ezetimibe+placebo&page=4&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ezetimibe+placebo&page=2&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-09T21:03:35.042Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03510884",
      "title": "An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypercholesterolaemia"
      ],
      "interventions": [
        {
          "name": "Alirocumab SAR236553 (REGN727)",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        },
        {
          "name": "Pravastatin",
          "type": "DRUG"
        },
        {
          "name": "Lovastatin",
          "type": "DRUG"
        },
        {
          "name": "Fluvastatin",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Cholestyramine",
          "type": "DRUG"
        },
        {
          "name": "Nicotinic acid",
          "type": "DRUG"
        },
        {
          "name": "Fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "Omega-3 fatty acids",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sanofi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 153,
      "start_date": "2018-05-31",
      "completion_date": "2022-08-05",
      "has_results": true,
      "last_update_posted_date": "2023-05-06",
      "last_synced_at": "2026-10-09T21:03:35.042Z",
      "location_count": 5,
      "location_summary": "Boca Raton, Florida • St Louis, Missouri • Charlotte, North Carolina + 2 more",
      "locations": [
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03510884"
    },
    {
      "nct_id": "NCT00185107",
      "title": "Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Colesevelam Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Simvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daiichi Sankyo",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 45,
      "start_date": "2005-03",
      "completion_date": "2005-10",
      "has_results": false,
      "last_update_posted_date": "2007-09-11",
      "last_synced_at": "2026-10-09T21:03:35.042Z",
      "location_count": 7,
      "location_summary": "San Diego, California • Ocala, Florida • Overland Park, Kansas + 4 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Edina",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00185107"
    },
    {
      "nct_id": "NCT00559962",
      "title": "Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "AEGR-733",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "DRUG"
        },
        {
          "name": "AEGR-733 and atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "AEGR-733 and fenofibrate",
          "type": "DRUG"
        },
        {
          "name": "AEGR-733 and ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aegerion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 260,
      "start_date": "2007-10",
      "completion_date": "2008-11",
      "has_results": true,
      "last_update_posted_date": "2018-02-23",
      "last_synced_at": "2026-10-09T21:03:35.042Z",
      "location_count": 15,
      "location_summary": "San Diego, California • Santa Rosa, California • Washington D.C., District of Columbia + 10 more",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Rosa",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00559962"
    },
    {
      "nct_id": "NCT01112423",
      "title": "Safety Study of BMS-823778 in Subjects With Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemia"
      ],
      "interventions": [
        {
          "name": "BMS-823778",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 60,
      "start_date": "2010-06",
      "completion_date": "2010-12",
      "has_results": false,
      "last_update_posted_date": "2015-10-12",
      "last_synced_at": "2026-10-09T21:03:35.042Z",
      "location_count": 6,
      "location_summary": "Little Rock, Arkansas • Lenexa, Kansas • Cincinnati, Ohio + 3 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Lenexa",
          "state": "Kansas"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "Norfolk",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01112423"
    },
    {
      "nct_id": "NCT00045812",
      "title": "SCH-58235 (Ezetimibe) to Treat Homozygous Sitosterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lipoidosis"
      ],
      "interventions": [
        {
          "name": "SCH-58235",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5,
      "start_date": "2001-03",
      "completion_date": "2004-04",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-09T21:03:35.042Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00045812"
    },
    {
      "nct_id": "NCT01766713",
      "title": "Ezetimibe Versus Placebo in the Treatment of Non-alcoholic Steatohepatitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non Alcoholic Steatohepatitis"
      ],
      "interventions": [
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Diego",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 50,
      "start_date": "2013-01",
      "completion_date": "2014-09",
      "has_results": true,
      "last_update_posted_date": "2020-07-14",
      "last_synced_at": "2026-10-09T21:03:35.042Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01766713"
    },
    {
      "nct_id": "NCT05266586",
      "title": "Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe as an Adjunct to HIS Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dyslipidemias",
        "High Cholesterol",
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "Obicetrapib",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe 10mg",
          "type": "DRUG"
        },
        {
          "name": "Obicetrapib placebo",
          "type": "OTHER"
        },
        {
          "name": "Ezetimibe placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "NewAmsterdam Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 119,
      "start_date": "2022-03-09",
      "completion_date": "2022-09-08",
      "has_results": true,
      "last_update_posted_date": "2024-07-03",
      "last_synced_at": "2026-10-09T21:03:35.042Z",
      "location_count": 16,
      "location_summary": "Los Angeles, California • Northridge, California • Ocala, Florida + 13 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Northridge",
          "state": "California"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        },
        {
          "city": "Pembroke Pines",
          "state": "Florida"
        },
        {
          "city": "Port Orange",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05266586"
    },
    {
      "nct_id": "NCT01047683",
      "title": "Efficacy and Safety of AMR101 (Ethyl Icosapentate) in Patients With Fasting Triglyceride (Tg) Levels ≥ 500 and ≤ 2000 mg/dL",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hypertriglyceridemia"
      ],
      "interventions": [
        {
          "name": "AMR101 (ethyl icosapentate) - 4 g/day",
          "type": "DRUG"
        },
        {
          "name": "AMR101 (ethyl icosapentate) - 2 g/day",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amarin Pharma Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 229,
      "start_date": "2009-12",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2022-04-25",
      "last_synced_at": "2026-10-09T21:03:35.042Z",
      "location_count": 18,
      "location_summary": "Sacramento, California • Golden, Colorado • Miami, Florida + 13 more",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Golden",
          "state": "Colorado"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ocala",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01047683"
    },
    {
      "nct_id": "NCT01375777",
      "title": "Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 411,
      "start_date": "2011-07-06",
      "completion_date": "2012-03-02",
      "has_results": true,
      "last_update_posted_date": "2022-11-08",
      "last_synced_at": "2026-10-09T21:03:35.042Z",
      "location_count": 41,
      "location_summary": "Birmingham, Alabama • Little Rock, Arkansas • Encinitas, California + 34 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Inglewood",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01375777"
    },
    {
      "nct_id": "NCT01763905",
      "title": "Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "Evolocumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo to Evolocumab",
          "type": "DRUG"
        },
        {
          "name": "Ezetimibe",
          "type": "DRUG"
        },
        {
          "name": "Placebo to Ezetimibe",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 307,
      "start_date": "2013-01-24",
      "completion_date": "2013-11-19",
      "has_results": true,
      "last_update_posted_date": "2020-07-20",
      "last_synced_at": "2026-10-09T21:03:35.042Z",
      "location_count": 20,
      "location_summary": "Carmichael, California • Los Angeles, California • Mission Viejo, California + 15 more",
      "locations": [
        {
          "city": "Carmichael",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Thousand Oaks",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01763905"
    }
  ]
}